Kinetiq

Biotech · Private

Subcutaneous enzyme replacement therapy formulation for Fabry disease using optimized GLA enzyme delivery

biokinetiq.com →
Grants
$523K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
2 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Subcutaneous Replacement Enzymes for Fabry Disease$211,668
Federal grantDepartment of Health and Human Services · Phase I · Subcutaneous Replacement Enzymes for Fabry Disease$261,668
Federal grantDepartment of Health and Human Services · Phase I · Subcutaneous Replacement Enzymes for Fabry Disease$50,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3144DINYA DNA INC—$3.8M
3145CARDIAC RSK3 INHIBITORS, LLC——
3146AJK BIOPHARMACEUTICAL LLC——
3147Kinetiq——
3148ExQor Technologies Inc——
3149Lung Biotechnology——
3150VIBE PHARMACEUTICALS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 4

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.